FCMV
GPCR icon

Foresite Capital Management VI’s Structure Therapeutics GPCR Stock Holding History

Foresite Capital Management VI’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-210,000
Closed -$4.36M – 16
2025
Q2 		$4.36M Sell
210,000
-210,000
-50% -$4.62M 2.45% 14
2025
Q1 		$7.27M Hold
420,000
– – 3.98% 8
2024
Q4 		$11.4M Buy
+420,000
New +$14.9M 5.08% 7

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Foresite Capital Management VI's GPCR Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 210,000 shares — an estimated $4.36M sold.

Foresite Capital Management VI first reported a position in GPCR in Q4 2024 and held it in 3 quarters. The position peaked at $11.4M in Q4 2024. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 210,000 Structure Therapeutics shares in Q3 2025, an estimated $4.36M.
  • Foresite Capital Management VI first reported a position in Structure Therapeutics in Q4 2024 and held it in 3 quarters.
  • Foresite Capital Management VI's Structure Therapeutics position peaked at $11.4M in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.